There is an unmet need for non-invasive biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) in non-specialized settings. We aimed to develop and validate a non-invasive test for diagnosing NASH in individuals with biopsy-proven nonalcoholic fatty liver disease (NAFLD).

acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study

Targher, Giovanni
Writing – Review & Editing
;
2021-01-01

Abstract

There is an unmet need for non-invasive biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) in non-specialized settings. We aimed to develop and validate a non-invasive test for diagnosing NASH in individuals with biopsy-proven nonalcoholic fatty liver disease (NAFLD).
2021
BMI, body mass index
CRN, Clinical Research Network
GAA, guanidine-acetic acid
HCV, chronic viral hepatitis C
NASH, nonalcoholic steatohepatitis
NPV, negative predictive value
Nonalcoholic steatohepatitis
PERSONS, Prospective Epidemic Research Specifically Of NASH
PPV, positive predictive value
SCr, serum creatinine
Se, sensitivity
Sp, specificity
primary care
ALT, alanine aminotransferase
AUROC, area under receiver operating characteristics
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration
HBV, chronic viral hepatitis B
NAFLD, nonalcoholic fatty liver disease
NAS, NAFLD Activity Score
T2DM, type 2 diabetes mellitus
e-GFR, estimated glomerular filtration rate
metabolic dysfunction-associated fatty liver disease
nonalcoholic fatty liver disease
scoring system
screening
AST, aspartate aminotransferase
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1050759
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 17
social impact